Axsome Therapeutics has released findings from its ENCORE Phase III trial, demonstrating that their investigational drug AXS-12 (reboxetine) significantly reduces cataplexy attacks, improves excessive daytime sleepiness and enhances overall functioning in individuals with narcolepsy. These results highlight reboxetine’s potential as a comprehensive treatment for this challenging sleep-wake disorder. Reboxetine, a norepinephrine reuptake inhibitor and cortical […]